ImmunityBio, Inc.
For the period ended Jun 9, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 9, 2026 · Filed Apr 30, 2026
Contents
Pay Versus Performance Table
Analysis.”
Pay Versus Performance Table
| Value of Initial Fixed $100 Investment Based on: | ||||||||
|---|---|---|---|---|---|---|---|---|
| Year(a) | SummaryCompensationTable Total for PEO ($) (b) | CompensationActually Paidto PEO ($) (1)(2)(c) | AverageSummaryCompensationTable Totalfor Non-PEO NEOs ($) (d) | AverageCompensation Actually Paidto Non-PEO NEOs ($) (1)(2)(e) | ImmunityBio TotalShareholderReturn ($) (3)(f) | Peer Group TotalShareholderReturn ($) (4) (g) | Net Loss ($M)(h) | Revenue ($M)(i) |
| 2025 | 12,716,953 | 6,222,909 | 5,761,037 | 2,920,536 | 14.85 | 119.92 | (351.5) | 113.3 |
| 2024 | 10,954,875 | 4,065,929 | 5,801,150 | 2,319,758 | 19.20 | 90.58 | (413.6) | 14.7 |
| 2023 | 1,156,903 | 262,372 | 961,711 | 622,399 | 37.66 | 91.84 | (583.9) | 0.6 |
| 2022 | 4,008,507 | 2,751,454 | 2,724,907 | 2,481,143 | 38.03 | 88.53 | (417.3) | 0.2 |
| 2021 | 29,016,727 | 10,356,288 | 2,888,272 | 1,170,403 | 45.61 | 99.37 | (349.8) | 0.9 |
(1)As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (SCT), the table below provides a reconciliation of the SCT amounts to the Compensation Actually Paid (CAP) amounts in the Pay Versus Performance table for Mr. Adcock and the average SCT and CAP amounts for our other NEOs for each of the last five years. The other Non-PEO NEOs for 2025 include Mr. Sachs, Dr. Soon-Shiong, and Ms. Lauer. The other Non-PEO NEOs for each of 2024, 2023, 2022, and 2021 include Mr. Sachs and Dr. Soon-Shiong.
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
| Required Adjustments to Summary Compensation Table Totals to Determine “Compensation Actually Paid” | ||||||||
|---|---|---|---|---|---|---|---|---|
| SummaryCompensationTable Total ($) · Summary CompensationTable Valueof StockAwards ($) · Summary CompensationTable Valueof OptionAwards ($) · Fair Valueas of YearEnd ofEquityAwardsGrantedDuring theYear ($) · Year-Over-YearIncrease(Decrease) inFair Value asof Year Endof UnvestedAwardsGranted inPrior Years ($) · Increase(Decrease)From PriorYear Endin FairValue ofAwards ThatVestedDuring theYear ($) · CompensationActuallyPaid ($) | ||||||||
| Year | (a) | (b) | (c) | (d) | (e) | (f) | (g)=(a)-(b)-(c)+(d)+(e)+(f) | |
| Richard Adcock | 2025 | 12,716,953 | 2,787,828 | 8,353,406 | 4,780,201 | (626,555) | 493,544 | 6,222,909 |
| Average of Other NEOs | 2025 | 5,761,037 | 1,226,643 | 3,675,499 | 2,103,288 | (216,284) | 174,637 | 2,920,536 |
(2)The fair value or change in fair value, as applicable, of equity awards was determined in accordance with ASC 718 by reference to (1) for RSU awards, the closing price of our common stock on the applicable measurement date and (2) for option awards, a Black-Scholes valuation model with updated assumptions for time to expiration, closing price of our common stock, volatility, and risk-free rate as of the applicable measurement date.
ImmunityBio, Inc. | 44 | 2026 Proxy Statement
(3)Pursuant to SEC rules, TSR reflects an initial investment of $100 in the company’s common stock on December 31, 2021. Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period (December 31, 2021 – December 31, 2025), assuming dividend reinvestment, and the difference between the share price at the end and the beginning of the measurement period by the share price at the beginning of the measurement period. The company has never paid cash dividends on its common stock.
(4)Peer Group TSR reflects an initial investment of $100 in the Nasdaq Biotechnology Index on December 31, 2021, which is the same index we used in the Stock Performance Graph in our Annual Report. Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period (December 31, 2021 – December 31, 2025), assuming dividend reinvestment, and the difference between the share price at the end and the beginning of the measurement period by the share price at the beginning of the measurement period.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.